Blood Res 2017; 52(1):
Published online March 27, 2017
https://doi.org/10.5045/br.2017.52.1.71
© The Korean Society of Hematology
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
2Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Correspondence to : Zeev Estrov. Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. zestrov@mdanderson.org
Since the aberrant mast cells did not meet the conventional diagnostic criteria of systemic mastocytosis (the presence of compact BM mast cell infiltrates), we concluded that the patient has LV-HES with a sub-diagnostic systemic mastocytosis as described by Pardanani et al. [1]. Patients with LV-HES commonly present with cutaneous and rheumatologic manifestations. In addition, the presence of monoclonal T cells with an abnormal immunophenotype and increased levels of Th2 cytokines is common in LV-HES patients [2]. Although these patients generally respond to steroids, some patients respond to imatinib even in the absence of
This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 and Award Number P01 CA049639 from the National Cancer Institute.
Morphologic and immunophenotypic features of the bone marrow biopsy and aspirate.
Flow cytometry analysis of bone marrow aspirate detected a minor population of aberrant T cells (about 0.52% of total cells) coexpressing CD4, CD5 with partial loss of CD7 (upper panel) and CD2 expression (not shown), and an aberrant population of cells coexpressing CD25 and CD117 mast cells (0.04%) (lower panel).
Blood Res 2017; 52(1): 71-73
Published online March 27, 2017 https://doi.org/10.5045/br.2017.52.1.71
Copyright © The Korean Society of Hematology.
Preetesh Jain1, Sa A. Wang2, C. Cameron Yin2, Yasmin Abaza1, Srdan Verstovsek1, and Zeev Estrov1*
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
2Department of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Correspondence to: Zeev Estrov. Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. zestrov@mdanderson.org
Since the aberrant mast cells did not meet the conventional diagnostic criteria of systemic mastocytosis (the presence of compact BM mast cell infiltrates), we concluded that the patient has LV-HES with a sub-diagnostic systemic mastocytosis as described by Pardanani et al. [1]. Patients with LV-HES commonly present with cutaneous and rheumatologic manifestations. In addition, the presence of monoclonal T cells with an abnormal immunophenotype and increased levels of Th2 cytokines is common in LV-HES patients [2]. Although these patients generally respond to steroids, some patients respond to imatinib even in the absence of
This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 and Award Number P01 CA049639 from the National Cancer Institute.
Morphologic and immunophenotypic features of the bone marrow biopsy and aspirate.
Flow cytometry analysis of bone marrow aspirate detected a minor population of aberrant T cells (about 0.52% of total cells) coexpressing CD4, CD5 with partial loss of CD7 (upper panel) and CD2 expression (not shown), and an aberrant population of cells coexpressing CD25 and CD117 mast cells (0.04%) (lower panel).
Morphologic and immunophenotypic features of the bone marrow biopsy and aspirate.
Flow cytometry analysis of bone marrow aspirate detected a minor population of aberrant T cells (about 0.52% of total cells) coexpressing CD4, CD5 with partial loss of CD7 (upper panel) and CD2 expression (not shown), and an aberrant population of cells coexpressing CD25 and CD117 mast cells (0.04%) (lower panel).